TR200000662T2 - Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi. - Google Patents

Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.

Info

Publication number
TR200000662T2
TR200000662T2 TR2000/00662T TR200000662T TR200000662T2 TR 200000662 T2 TR200000662 T2 TR 200000662T2 TR 2000/00662 T TR2000/00662 T TR 2000/00662T TR 200000662 T TR200000662 T TR 200000662T TR 200000662 T2 TR200000662 T2 TR 200000662T2
Authority
TR
Turkey
Prior art keywords
unnatural
bone volume
increasing bone
selective agonists
agonist
Prior art date
Application number
TR2000/00662T
Other languages
English (en)
Inventor
Richard Hartke James
Walden Lundy Mark
Anthony Delong Mitchell
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200000662T2 publication Critical patent/TR200000662T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus kemik hacmini arttirmanin yeni yöntemleri ile ilgilidir, bir dogal olmayan seçici FP agonistinin bu tür bir tedaviye ihtiyaci olan bir hastaya uygulanmasindan olusur. Bu bulus ayrica kemik düzensizliklerinin tedavisi veya önlenmesinin bir yöntemi ile ilgilidir, bir dogal olmayan seçici FP agonistinin bu tür bir tedaviye ihtiyaci olan bir hastaya uygulanmasindan olusur.
TR2000/00662T 1997-09-09 1998-09-04 Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi. TR200000662T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
TR200000662T2 true TR200000662T2 (tr) 2000-07-21

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00662T TR200000662T2 (tr) 1997-09-09 1998-09-04 Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.

Country Status (20)

Country Link
US (1) US6156799A (tr)
EP (1) EP1045694A1 (tr)
JP (1) JP2001515864A (tr)
KR (1) KR20010023840A (tr)
CN (1) CN1269721A (tr)
AR (1) AR013479A1 (tr)
AU (1) AU739275B2 (tr)
BR (1) BR9811780A (tr)
CA (1) CA2303800A1 (tr)
CO (1) CO4980882A1 (tr)
HU (1) HUP0004581A2 (tr)
ID (1) ID24827A (tr)
IL (1) IL134760A0 (tr)
NO (1) NO20001171L (tr)
PE (1) PE119099A1 (tr)
PL (1) PL339288A1 (tr)
SK (1) SK3412000A3 (tr)
TR (1) TR200000662T2 (tr)
WO (1) WO1999012551A1 (tr)
ZA (1) ZA988228B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513826A (en) * 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
CA2364948C (en) * 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
WO2000051585A2 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
CN1498385A (zh) 2000-08-29 2004-05-19 X图像量析的方法与装置
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
CA2446296A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods to diagnose treat and prevent bone loss
JP4273407B2 (ja) * 2001-07-23 2009-06-03 小野薬品工業株式会社 Ｅｐ４アゴニストを有効成分とする骨量低下疾患の治療剤
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
KR20050013529A (ko) * 2002-02-07 2005-02-04 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 약물 전달용 폴리무수물 치료 화합물
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
CA2519187A1 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
CA2539487A1 (en) * 2003-09-19 2005-03-31 Imaging Therapeutics, Inc. Method for bone structure prognosis and simulated bone remodeling
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
EP2061376A2 (en) * 2006-09-15 2009-05-27 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
AU3607293A (en) * 1992-02-05 1993-09-03 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
PL339288A1 (en) 2000-12-04
NO20001171L (no) 2000-05-09
SK3412000A3 (en) 2000-12-11
KR20010023840A (ko) 2001-03-26
NO20001171D0 (no) 2000-03-07
ZA988228B (en) 1999-03-09
EP1045694A1 (en) 2000-10-25
WO1999012551A1 (en) 1999-03-18
HUP0004581A2 (hu) 2001-05-28
US6156799A (en) 2000-12-05
PE119099A1 (es) 2000-02-03
ID24827A (id) 2000-08-24
CO4980882A1 (es) 2000-11-27
IL134760A0 (en) 2001-04-30
CN1269721A (zh) 2000-10-11
AR013479A1 (es) 2000-12-27
AU9219298A (en) 1999-03-29
AU739275B2 (en) 2001-10-11
CA2303800A1 (en) 1999-03-18
JP2001515864A (ja) 2001-09-25
BR9811780A (pt) 2000-09-12

Similar Documents

Publication Publication Date Title
TR199902033T2 (tr) Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EA200000563A1 (ru) Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена
EA199801044A1 (ru) Модуляторы регенерации тканей
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
ES2153337T1 (es) Inhibidores de raf-quinasa.
DK0987998T3 (da) Decellulering af væv
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
DE59913784D1 (de) Verwendung von Thiazolidinderivaten als antihyperglykämische Mittel
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
FI862407A7 (fi) Menetelmä luun huokoistamisen hoitamiseksi.
BG63122B1 (bg) Съединения и методи за лечение на рак
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
DK0855896T3 (da) Fremgangsmåde til oxidationsfarvning af keratinfibre og sammensætning, der benyttes under denne fremgangsmåde
ID24827A (id) Metoda peningkatan volume tulang dengan menggunakan agonis fp selektif yang terjadi secara non-alami
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
TR200002646T2 (tr) Yeni eprosartan bileşimleri
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
PE20399A1 (es) Muteina ob
DE69903716D1 (de) Kombination von einem inversen agonisten des gaba-a alpha-5 rezeptor subtyps und nicotinerge agonisten
ES2175842T3 (es) Antagonistas de kv2.1.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung